skinny.

Latest / Lung Cancer Considered

FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.